Skip to main content

GreenLight XPS™

Laser Therapy System

The GOLIATH Study: GreenLight™ Laser 
Therapy vs. TURP

The GOLIATH Study1, 2, 3  was the first head-to-head trial to compare the safety and efficacy of the GreenLight XPS™ 180 W Laser Therapy System with transurethral resection of the prostate (TURP). It was conducted as a prospective, randomized, multicenter study in nine European countries. A total of 291 patients from 29 sites were enrolled between April 2011 and September 2012.

Key Resources

Product Instructions Indications, Safety, and Warnings Reimbursement
Request A Sales Rep Visit
The primary objective of the trial was to determine the non-inferiority of the GreenLight XPS 180 W system compared with TURP using the International Prostate Symptom Score (IPSS), maximum flow rate (Qmax) and the proportion of patients who were complication free was also measured.
Map of Europe.

Meet the Primary Investigator

Listen to one of the GOLIATH study Principal Investigators, Professor Alexander Bachmann, discuss some of the key findings of the GOLIATH study.

Equally Effective. Equally Safe.

At the 6 month follow up, the GOLIATH Study showed that the GreenLight XPS system was equivalent to TURP in reducing benign prostatic hyperplasia (BPH) symptoms (IPSS) and prostate volume as well as improving quality of life (QoL). The two treatments also had similar Qmax and Dysuria rates. These clinical outcomes remained true in the 24 month follow up.

Graph of GOLIATH Study results.

GreenLight Laser Therapy is superior to TURP for Healthcare Facility Length of Stay

Patients treated with GreenLight therapy had a significantly shorter mean length of catheterization, time until stable health and hospitalization.

Bar Graphs: Length of Catheterization, Time until Stable Health, Length of Hospital Stay.

GreenLight Procedure Results in Fewer Complications

The proportion of patients who were complication-free during the first six months was comparable between the GreenLight XPS system and TURP. These results continued to be comparable at 24 months. However, there was a statistically significant difference in early adverse events (48 hours to 30 days), with 12 complications in the TURP group and zero in the GreenLight XPS arm.

Days Spent Complication-Free bar graph.

Presentation Deck

Interested in sharing the GOLIATH Study for presenting GOLIATH at your facility?

Download a slide deck
  

Infographic

Learn more about the GOLIATH Study by downloading an infographic summary.

Download Infographic
Top